(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-0.15%) $77.99
(0.37%) $2.15
(0.06%) $2 310.10
(0.36%) $26.79
(0.09%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.12%) $0.797
(0.35%) $91.45
Quarter results tomorrow
(tns 2024-05-06)
Expected move: +/- 0.00%
0.00% $ 0.0750
Live Chart Being Loaded With Signals
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron...
Stats | |
---|---|
Dzisiejszy wolumen | 701.00 |
Średni wolumen | 16 518.00 |
Kapitalizacja rynkowa | 5.57M |
EPS | $0 ( 2024-02-09 ) |
Następna data zysków | ( $0 ) 2024-05-06 |
Last Dividend | $0.120 ( 2019-09-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.50 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-16 | Read Randolph C | Buy | 84 550 | Common Stock |
2023-06-14 | Read Randolph C | Buy | 15 000 | Common Stock |
2022-06-09 | Firestone Jaffrey Adam | Buy | 0 | |
2021-08-13 | Couchman Jonathan | Sell | 57 500 | Common Stock, $0.01 par value |
2021-08-13 | Couchman Jonathan | Sell | 50 000 | Common Stock, $0.01 par value |
INSIDER POWER |
---|
100.00 |
Last 86 transactions |
Buy: 34 996 838 | Sell: 942 903 |
Enzon Pharmaceuticals, Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Enzon Pharmaceuticals, Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $0.0185 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $0.0185 |
FY | 2022 |
Przychody: | $26 000.00 |
Zysk brutto: | $26 000.00 (100.00 %) |
EPS: | $-0.00250 |
FY | 2021 |
Przychody: | $701 000 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.0300 |
Financial Reports:
No articles found.
Enzon Pharmaceuticals, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $2.00 | 2012-12-06 |
Last Dividend | $0.120 | 2019-09-30 |
Next Dividend | $0 | N/A |
Payout Date | 2019-10-15 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | $5.38 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.6 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RSRV | Ex Dividend Junior | 2023-06-06 | Annually | 0 | 0.00% | |
NUVR | Ex Dividend Junior | 2023-06-02 | Quarterly | 0 | 0.00% | |
FMFG | Ex Dividend Knight | 2023-06-01 | Semi-Annually | 0 | 0.00% | |
CZFS | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
BEBE | Ex Dividend Junior | 2023-09-18 | Quarterly | 0 | 0.00% | |
TBTC | Ex Dividend Junior | 2023-08-31 | Sporadic | 0 | 0.00% | |
QNBC | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
ISBA | Ex Dividend Knight | 2023-09-26 | Quarterly | 0 | 0.00% | |
FKYS | Ex Dividend Knight | 2023-09-06 | Quarterly | 0 | 0.00% | |
CNLHN | Ex Dividend Knight | 2023-08-09 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | 0.0288 | 1.200 | 9.04 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0390 | 1.500 | -0.678 | -1.017 | [0.1 - 1] |
payoutRatioTTM | 0.929 | -1.000 | 0.714 | -0.714 | [0 - 1] |
currentRatioTTM | 27.62 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 27.43 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 27.43 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0176 | 2.00 | 9.99 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0176 | 2.00 | 9.99 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.15 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 4.05 | 1.000 | 9.69 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0390 | 2.50 | -0.436 | -1.017 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0176 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0176 | 2.00 | 9.99 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.929 | 1.500 | 0.714 | -0.714 | [0 - 1] |
pegRatioTTM | -0.165 | 1.500 | -4.43 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | 2.05 |
Enzon Pharmaceuticals,
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej